Skip to main content

Electric SUV showdown: Edmunds compares the revamped Toyota bZ to the Tesla Model Y

Once you’ve decided to buy an electric vehicle, the exciting but tricky part is choosing which one to get. For a growing number of car shoppers, an electric SUV makes the most sense for everyday life. The latest models have enough range to handle everyday driving and the occasional trek out of town without much of an issue. They’re also roomy for your family and have some innovative technology features. But which one to get? That’s where the Tesla Model Y and Toyota bZ come in.

Tesla’s best-selling EV gets a round of updates for 2026 that include revised styling, a smoother ride and a more upscale cabin. But Toyota’s all-electric SUV shouldn’t be counted out. It has been thoroughly overhauled for 2026, and the result is a much more compelling proposition than the outgoing model. Edmunds’ experts put these two electric SUVs head-to-head to find out which one deserves a spot in your driveway.

Range and charging

Formerly known as the bZ4X, Toyota’s first all-electric SUV has been so extensively revised that it now carries a new name. Pleasingly, range has improved considerably. The front-wheel-drive version of the 2026 bZ can go up to 314 miles on a single charge, according to EPA estimates. Edmunds has verified that in its own independent testing, with a test bZ covering 331 miles, an impressive result for a small electric SUV.

As with the bZ, different versions of the Model Y have varying range estimates. The longest comes from the Premium Rear-Wheel Drive, which can go an EPA-estimated 357 miles. Edmunds hasn’t range tested that Model Y version, but other tested Model Ys have matched their EPA estimates.

Edmunds also tested the bZ and Model Y for charging speeds at a public fast-charging station. Both SUVs yielded similar results and could potentially add up to about 100 miles of range in 15 minutes. The Model Y is a bit more convenient to charge at Tesla’s nationwide network of Supercharger stations, however.

Winner: Model Y

Driving experience and interior space

The Tesla Model Y remains one of the more engaging electric SUVs to drive. It accelerates quickly, has a smooth ride, and feels sporty and stable when going around corners. The cabin is well insulated from road and wind noise, and the front seats offer a wide range of adjustments for comfort during longer drives.

While the outgoing bZ4X felt sluggish, the bZ flips the script with brisk acceleration in both single- and dual-motor configurations. The front-wheel-drive bZ actually outpaced the base Model Y Rear-Wheel Drive in Edmunds’ 0-to-60 mph testing, while an all-wheel-drive bZ trailed just behind the Model Y All-Wheel Drive in the same test. The bZ also has a comfortable ride over bumps, but it doesn’t feel as composed as the Model Y when cornering.

Interior space is significantly better in the Model Y. It has more rear legroom, which allows adults to be more comfortable and provides extra space for installing bulky rear-facing child safety seats. The Model Y also has more cargo space and a few more useful spaces to store small items.

Winner: Model Y

Technology

Tesla’s infotainment system remains a highlight, with a clean interface and quick response. Dual wireless chargers add convenience, and Tesla’s advanced driver assistance features help set it apart. The Full Self-Driving (Supervised) feature is particularly notable for allowing for hands-free driving on both highways and city streets. However, the lack of Apple CarPlay and Android Auto smartphone integration may be a sticking point for some buyers.

Toyota counters with a new 14.1-inch touchscreen infotainment system that’s easy to use and supports wireless connectivity Apple CarPlay and Android Auto. Dual wireless phone chargers are up front, and a total of four fast-charging USB-C ports are on board. Standard driver assistance features are comprehensive. The bZ also has a hands-free driving feature, but it only works at low speeds on the highway.

Winner: Model Y

Pricing and value

The base Model Y Rear-Wheel Drive starts at $41,630, including destination. However, it’s missing some features you’ll probably want in an EV. The Premium version of the Model Y is what you want because of its added power, slightly greater range and a more upscale interior. A Model Y Premium All-Wheel Drive costs $51,630.

The Toyota bZ starts at $36,495 and comes well equipped for the price, especially when you consider the improved performance and range now on offer. The top-line bZ Limited adds even more features and is comparable to the Model Y Premium. It costs $46,895 in its available all-wheel-drive configuration.

Winner: bZ

Edmunds says

The Toyota bZ’s improvements make it a far more appealing electric SUV than before, and its low starting price strengthens its appeal for value-focused buyers. That said, the Tesla Model Y continues to set the benchmark in this segment with its superior technology, performance and overall refinement. While Toyota has made meaningful progress, the Model Y remains the better choice.

_____

This story was provided to The Associated Press by the automotive website Edmunds. Bradley Iger is a contributor at Edmunds.

When you have advanced prostate cancer: What living with the disease looks like

By WTOP Staff
(CNN) — “How long do I have to live ?”When I tell a patient he has prostate cancer, this is usually what he asks me first.With early-stage or low-grade prostate cancer, I can offer strong reassurance: Your life expectancy is good — expect a five-year relative survival rate of greater than 99% with treatment. Simply put, most men will not die from low-grade prostate cancer.However, once the cancer has spread outside the prostate to the bones and other organs the answer becomes more difficult. Treatment has changed dramatically over the past decade for advanced prostate cancer. New drugs, better imaging and the earlier use of combined therapies are helping men live longer.In a video released July 15, former President Joe Biden gave an update on his prostate cancer, saying he was receiving treatments that have been going well. In May 2025, Biden officially announced that he had an aggressive form of prostate cancer that had spread to his bones. Since then, based on official updates, he has continued hormone therapy, completed a course of radiation and maintained a public presence.His diagnosis brought renewed attention to prostate cancer screening and treatment. Now, more than a year later, his cancer journey offers an opportunity to examine what has changed in the treatment of advanced prostate cancer — and the hope these offer men living with the disease.I recently saw a patient who was diagnosed three years ago with cancer that had already spread to multiple areas in his bones. Since then, he has taken cruises, traveled with his family and spent weekends babysitting his grandchildren.He gets tired and cannot garden the way he once did. But he is still alive and considers every day a blessing. His experience, and what we see with Biden, shows what living with metastatic prostate cancer can look like today.Understanding survival ratesIf they haven’t asked their doctor already, many patients go online and find five-year survival rates, but every number they may find online comes with a huge asterisk.The American Cancer Society reports five-year relative survival of greater than 99% when prostate cancer is found in or near the prostate. The figure drops to 38% when it has reached distant parts of the body.But that number is based on large groups of men treated years ago. It does not fully reflect the impact of newer treatments — or account for an individual man’s age, overall health and response to therapy.Survival statistics describe groups of patients but do not predict what will happen to one person. That is why the 38% figure cannot tell us how long Biden — or any individual patient — will live. These patients’ outlook depends on details of their cancer and how they are responding to treatments.It’s treated more aggressively nowA man diagnosed with metastatic prostate cancer a decade ago and a man diagnosed today would not receive the same treatment. The thinking now is to use our best treatments early instead of holding back.For years, doctors began with hormone therapy — usually injections that lower testosterone — and saved other treatments until the cancer stopped responding.Today, those injections are often combined from the start with a newer hormone-blocking drug and/or chemotherapy. These combinations have helped men live longer and are one of the biggest shifts of the past decade.What Biden’s diagnosis told usThere are three details about Biden’s cancer that help doctors like me understand how aggressive it is and how to manage it effectively. Official statements highlighted that his cancer had a Gleason score of 9. The cancer had spread to his bones, and it was labeled as hormone-sensitive.The Gleason score is assigned after a pathologist examines biopsy samples. Scores typically range from 6 to 10, with higher numbers indicating more aggressive cancer. A score of 9 falls into the most aggressive category. However, the score alone cannot tell us whether the cancer has spread outside the prostate.When prostate cancer spreads, the most common destination is the bones — particularly the spine, pelvis and ribs. It can also reach organs such as the lungs or liver. Once it has reached distant parts of the body, it is generally not curable, but treatment can put a brake on it for years.Prostate cancer can also be hormone-sensitive or hormone-resistant. Because it typically relies on testosterone to grow, lowering the hormone or blocking its effects can help control the cancer. Hormone-sensitive means it still responds to these treatments.Over time, most advanced or metastatic prostate cancers find ways to grow despite low testosterone levels, which mean they are now hormone-resistant. Lowering testosterone alone is no longer enough to control the cancer, so doctors have to turn to additional therapies.Knowing if the cancer has spreadThe most sensitive imaging test available today is a PSMA PET scan. It uses a radioactive tracer that seeks out a protein found on the surface of prostate cancer cells. Areas containing cancer may appear as bright spots, helping identify where the cancer has spread. The American Urological Association supports using this imaging test to determine whether high-risk prostate cancer has spread and to help establish its stage.A traditional bone scan, used for decades, highlights areas where bone is reacting to injury or disease. It remains an alternative imaging option, but PSMA PET is increasingly replacing its use.What areas light up and where matter when deciding on treatments. A single spot in the spine and cancer that has spread to the liver are both called stage 4, but they are not the same disease and may not be treated the same way.Doctors also consider how much cancer has spread. We label it as “low-volume” disease when the cancer has reached a limited number of areas. High volume is when the spread is more widespread or has reached other organs such as the liver or lungs.Both require treatment that works throughout the body. Treatment for metastatic disease generally includes therapy that works throughout the body. For men with low-volume disease, adding radiation to the prostate may also help them live longer.Biden has completed a course of radiation, but his team has not disclosed what area was treated or enough detail to determine whether his cancer would be considered low- or high-volume.Treatment has become more preciseBeyond starting more treatments earlier, doctors can increasingly tailor therapy to the biology of an individual man’s cancer. We can now test both the tumor and a patient’s own DNA for mutations that help guide treatment.Roughly 1 in 10 men with metastatic prostate cancer carries an inherited mutation affecting the body’s ability to repair DNA. The best known are BRCA1 and BRCA2, the same genes linked to some breast and ovarian cancers.Certain mutations found in the tumor or inherited DNA may make targeted drugs called PARP inhibitors an option. If a mutation is inherited, it also gives family members information they can act on through genetic counseling, testing and earlier screening.Another advance is radioligand therapy. If a scan shows that cancer cells carry a protein called PSMA, doctors can attach radiation to a molecule that seeks out that protein. Delivered through an IV, it targets cancer cells throughout the body. This approach was expanded last year to more men whose cancer had become hormone resistant.Living longer can come with costsEvery treatment can cause side effects. With hormone therapy, one of the first is often hot flashes, similar to what women experience during menopause. These are not dangerous, but they can affect a man’s quality of life.Fatigue is also common. Testosterone helps maintain muscle, so lowering it can reduce strength and energy. Regular walking and resistance training can help preserve muscle and reduce fatigue.The side effect almost no one talks about is loss of sex drive or low libido. At diagnosis, most men are thinking about staying alive, not their libido. But months later, it often matters. It is worth discussing with your care team and your partner rather than assuming it is simply the price of treatment.The side effect I worry about most is weaker bones. Low testosterone reduces bone density, while cancer deposits can weaken the bone’s structure. Follow-up care should include exercise, a bone-density scan, and ensuring adequate levels of calcium and vitamin D. For men with hormone-resistant cancer that has spread to bone, bone-protecting drugs can reduce the risk of fractures and other complications.New or worsening back pain, especially with leg weakness, numbness or trouble controlling the bladder or bowels? These could mean the cancer is pressing on the spinal cord. It is a true medical emergency that requires immediate attention.Cancer care requires a team approachIdeally, several doctors work together to coordinate a patient’s care. The urologist is often the starting point. A medical oncologist manages treatments that work throughout the body, while a radiation oncologist targets specific areas, whether that is the prostate itself or a painful bone lesion. The primary care doctor helps protect the patient’s heart and bones and looks after the person’s overall health.A man’s age, other medical conditions, ability to tolerate side effects and goals for treatment all shape treatment plans. Two men with nearly identical test results may be offered — or choose — different paths based on their health and priorities.Good communication among doctors is essential, but gaps can happen. Being your own advocate means knowing who is on your care team, asking questions and understanding your options.I also recommend bringing someone you trust to important visits for support and to take notes and help you remember what was discussed.More treatments, better testing offer hopeFor men worried about prostate cancer, talk with your health care provider about the benefits and risks of PSA testing. Black men and those with a strong family history should begin that conversation in their 40s. New urinary symptoms are often not cancer, but they still deserve attention, as does blood in the urine or semen, unexplained weight loss and/or persistent back or bone pain.For men living with advanced prostate cancer, there is reason for hope. There are more treatments and better testing than there were a decade ago, and good care pays attention to how a man feels, not just to what his scans show.The-CNN-Wire™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
Read Next Story

Related Stories

Superman
Lifestyle News
This is the headline
June 29, 2026
Superman

This is the headline

Photo Sep 24 2025 5 14 29 PM 1672x1254

test

Obama Presidential Center

Inside Obama's presidential museum opening this month: The cost, the books and a beehive

Obama Presidential Center

Presidential museum showcases political and personal sides of Obama with sprawling community campus

Be Well Admin Dates

A new kind of date makes personal to-do lists a reason to get together with friends